Polypoidal choroidal vasculopathy (PCV) is a subtype of exudative age-related macular degeneration (AMD) that is most prevalent in Asian populations but is becoming increasingly recognized in populations around the world.1-3 The importance of recognizing PCV is that it is a subtype of exudative AMD that has been associated with resistance to antivascular endothelial growth factor (anti-VEGF) injections, which has become standard treatment for most cases of active exudative AMD.1,2 Therefore, finding a good treatment option for PCV would benefit many patients around the world.